Market News & Trends
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation
Abeona Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy program for patients with Recessive…
Sanofi Completes the Acquisition of Protein Sciences
Sanofi recently announced it has completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, CT. This completion follows Federal Trade Commission…
Huber Closes $630-Million Sale of Silica Business to Evonik
The J.M. Huber Corporation has completed the sale of the Silica business unit of Huber Engineered Materials (HEM) to Evonik Industries AG, a global specialty…
Roquette Completes Acquisition, Reinforces Ambition of Being Excipient Leader
Roquette, a global leader in innovative plant-based ingredients, recently announced it has completed the acquisition of Itacel from Blanver. Itacel is a leading player…
Dr. Christian Fischer to Succeed Uwe Röhrhoff as CEO of Gerresheimer AG
With effect from September 1, 2017, Dr. Christian Fischer (53) is to assume responsibility as Chief Executive Officer of Gerresheimer AG. He succeeds Uwe Röhrhoff…
Novartis Injection Could Prevent Heart Attacks, Slash Cancer Risk
By Ben Spencer, Medical Correspondent Thousands of lives could be saved thanks to a new heart drug hailed as the biggest breakthrough since…
Enteris Biopharma Doses First Woman in Phase 2a Clinical Trial
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, recently announced the first woman has been dosed in…
Jupiter Orphan Therapeutics Receives Orphan Drug Designation
Jupiter Orphan Therapeutics, Inc. recently announced it has received notification from the US Food and Drug Administration (FDA) that its Orphan Drug Designation request for…
PharmAkea Announces Successful Completion of a Phase 1 Trial
PharmAkea, Inc. recently announced it has successfully completed a Phase 1 single and multiple ascending dose (SAD/MAD) clinical study with PAT-1251, its novel, small-molecule LOXL2…
REGENXBIO to Acquire Dimension Therapeutics
REGENXBIO Inc. and Dimension Therapeutics, Inc. recently announced they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction…
Intra-Cellular Therapies Announces Positive Regulatory Update
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, recently announced that the U.S. Food and…
SiO2 Medical Products & Sanaria Sign Agreement for Cryogenic Vials
SiO Medical Products, Inc., a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical packaging, labware, and consumables products, and Sanaria Inc., a U.S.-based developer, manufacturer,…
Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line
Ajinomoto Althea, a leading service provider of biopharmaceutical contract development and manufacturing drug programs, announces the installation and launch of a new high-performance sterile…
Cardiovascular Disease - Innovation Within Dyslipidemia, Heart Failure & Thrombosis Set to Reduce High CVD Mortality Rate
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension,…
Monsanto & ToolGen Announce Global Licensing Agreement
Monsanto Company and ToolGen, Inc. recently announced the companies have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop…
Portola Pharmaceuticals Announces BLA Resubmission Accepted for Review
Portola Pharmaceuticals Inc. recently announced the US FDA has found its resubmitted Biologics License Application (BLA) for AndexXa (andexanet alfa) to be acceptable for review,…
Fortress Biotech Forms New Subsidiary to Develop Novel AAV Gene Therapy Treatments
Fortress Biotech, Inc. recently announced the formation of a new subsidiary company, Aevitas Therapeutics, Inc., to develop novel gene therapy approaches for complement-mediated diseases. The…
PolyPid Completes Enrollment in Phase Ib/II Study of D-PLEX
PolyPid Ltd. recently announced the completion of enrollment in its Phase Ib/II study of D-PLEX (Doxycycline/Polymer-Lipid Encapsulation Matrix), the company’s lead product candidate, for the…
Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study
Mateon Therapeutics, Inc. recently announced results from its second scheduled interim analysis of the ongoing Phase 2/3 FOCUS study evaluating CA4P in combination with bevacizumab…
Fate Therapeutics Announces Issuance of Patent Covering Use of Viral Transduction Enhancers
Fate Therapeutics, Inc. recently announced the US Patent and Trademark Office has issued US Patent No. 9,675,641 covering the use of prostaglandins as viral transduction…
